13 papers in the library · 29 citations · publishing 2012-2026
JAMA Network Open September 29, 2026 Otto Simonsson, Melissa Bradley, Joshua Curtis Black et al.
This cross-sectional study describes health outcomes attributed to recent use of psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a nationally representative survey of US adults.
Psychedelics September 29, 2026 Karilynn M Rockhill, Nicole Schow, Dean Garibaldi et al.
Objective In 2024, the United States had the highest prevalence of psychedelic use recorded, but reliability of self-report data in surveys has not been rigorously assessed. Our objective was to quantify the reliability of self-report across 17 psychedelic and dissociative substances in an adult population sampled from the National Survey Investigating Hallucinogenic Trends (NSIHT). Methods In...
Journal of Medical Internet Research April 27, 2026 Karilynn M Rockhill, Elizabeth A Bemis, Nicole Schow et al. 2 citations
Mainstays of pharmacoepidemiology are large, representative, behavioral surveys, which focus on many drugs with few detailed behaviors. Smaller, targeted studies measure drug-specific patterns but without explicit generalizability assumptions; the evidence generated is narrow. In this cross-sectional survey study, we outline an estimation framework based on data fusion and combine two surveys:...
Journal of Psychoactive Drugs March 16, 2026 Faith E Lyons, Karilynn M Rockhill, Evelyn J Fox et al.
Expanding regulation and increased use of psychedelic substances requires surveillance of behaviors and health outcomes in the United States. Widely comprehendible terminology is important for surveys. The objective of this study was to determine what psychedelic terminology is preferred among adults who used a psychedelic in the past 12 months. A cross-sectional survey measuring psychedelic...
JAMA March 12, 2026 Joshua C. Black, Gabrielle E. Bau, Ryan Cook et al. 2 citations
This survey study examines the estimated increase in 12-month psilocybin use in Oregon and Colorado associated with decriminalization.
Journal of Addiction Medicine January 15, 2026 Dale Terasaki, Nathan Sackett, Andrew A. Monte
The psychedelic substance, ibogaine, has garnered growing interest among policymakers, researchers, and the public in its potential use for opioid use disorder (OUD). Many states are allocating significant funds to investigate it further. However, some proponents of ibogaine are framing it in opposition to (versus complementary to) standard, mortality-reducing medications for OUD (MOUD)....
Annals of emergency medicine June 30, 2025 Joshua C. Black, Karilynn M Rockhill, Evelyn J Fox et al. 4 citations
Oregon and Colorado have legalized possession of natural psychedelic drugs. We assessed if travel to use psychedelics in decriminalized states is occurring and compared the use patterns of travelers with nontravelers. The National Survey Investigating Hallucinogen Trends is a cross-sectional behavioral survey fielded from April to June 2024 to every US state. The survey asks whether individuals...
International Journal of Mental Health and Addiction April 1, 2025 Joshua C. Black, Nicole Schow, Hannah L. Burkett et al. 3 citations
Psychedelic-assisted therapy could transform treating psychiatric illness, but harms from exacerbating substance use disorder (SUD) among adults with psychiatric illness using psychedelics have not been studied. A cross-sectional survey in the US was used to test whether Drug Abuse Screening Test scores (DAST-10, validated instrument predicting SUD) were more severe when psychiatric illnesses...
Annals of emergency medicine December 1, 2024 Mark W Simon, Heather A Olsen, Christopher O Hoyte et al. 12 citations
Psychedelic substances use is increasing in the United States (US). The approval of new psychedelic drugs and legalization of natural psychedelic substances will likely further increase exposures and subsequent adverse events. The study objective is to describe the clinical effects, therapies, and medical outcomes of patients with psychedelic exposures reported to US poison centers. We...
Addiction June 17, 2024 Philip Todd Korthuis, Adrianne R Wilson-Poe, Joshua C. Black et al. 1 citation
As psychedelic use expands, the number of adverse effects will increase proportionally. New frameworks for monitoring safety outcomes on a population level are required to limit potential harms. Darke et al. characterized 33 lysergic acid diethylamide (LSD) and 10 psilocybin-related deaths in Australia between 2000 and 2023 using the country's sophisticated national coroner data system....
Nature Mental Health May 1, 2024 Joshua C. Black, Andrew A. Monte, Nabarun Dasgupta et al. 5 citations
The encouraging results of late-phase clinical trials investigating psychedelic-assisted psychotherapy suggests that US Food and Drug Administration approval and subsequent expansion of use is imminent in the USA. Without fit-for-purpose postmarket surveillance to proactively monitor utilization by patients and providers, there is a risk that the real-world benefits of psychedelic-assisted...
Substance Use & Misuse June 7, 2018 Jacob Fox, Alexis Smith, Alexander Yale et al.
Drugs of abuse (DOA) are widely used in the United States and are ubiquitous at outdoor music festivals. Attendees at music festivals are at high-risk for novel psychoactive substance (NPS) use, which is becoming more prevalent worldwide. No U.S. studies have employed an qualitative approach to investigate the etiologies of both traditional DOA and NPS use amongst music festival attendees. The...
Annals of emergency medicine October 2012 Christopher O Hoyte, Jeena Jacob, Andrew A. Monte et al.
Δ-9-Tetrahydrocannabinol homologs have been increasingly abused since their introduction in 2004. Such products were used as a "legal high" for those wishing to experience cannabinoid effects while evading basic drugs-of-abuse testing. We describe a series of exposures to products marketed as synthetic cannabinoids to better characterize the clinical effects in these patients. All...